Factors influencing drug switching and changes in low-density lipoprotein-cholesterol levels with atorvastatin: a real-world observational study

Lipids in Health and Disease - Tập 22 Số 1
Yu-Cheol Lim1, Eui-Kyung Lee1, Mi-Hai Park1
1School of Pharmacy, Sungkyunkwan University, Suwon, Gyeonggi-do, South Korea

Tóm tắt

Abstract Background Although generic drugs have been approved with the assurance of interchangeable applications with original drugs, some physicians, and patients still view their efficacy and interchangeability negatively. Using real-world data, we aimed to determine factors that impact switching between drugs that contain the same active ingredient, i.e., atorvastatin, and, in turn, whether this ‘switch’ could alter clinical outcomes. Methods Using the National Health Insurance Service senior cohort, a retrospective cohort study was conducted to assess patients who had newly started atorvastatin 10 mg and had at least two records of national health examinations from 2010 to 2014. Drug switching, which was defined as a change in the atorvastatin product administered 90 days before the first and second examinations, was assessed. Greedy propensity score matching (1:2) was performed between switchers and non-switchers to control for potential confounders. Factors influencing switching were analyzed using multivariate logistic regression to estimate odds ratios and 95% confidence intervals (CIs). Changes in low-density lipoprotein-cholesterol (LDL-C) levels attributable to drug switching were evaluated using difference-in-differences regression. Results A total of 1,588 patients were included, of whom 25.3% switched drugs (1,187 non-switchers and 401 switchers). Compared to patients taking generics before the first examination, those taking the original drugs had a lower odds ratio (0.31; 95% CI [0.21, 0.46]) for subsequent drug switching. A change in medical institution was associated with a significantly higher odds ratio (6.83; 95% CI [4.66, 10.02]). There were no significant differences in LDL-C alterations between switchers and non-switchers (0.42 mg/dL; 95% CI [-2.29, 3.13]). Conclusion The type of first-time drug administered and changes in medical institution can influence drug switching. No significant changes in LDL-C values were observed in the various switching scenarios between the original and generic drugs, suggesting their interchangeable application in real-world clinical practice.

Từ khóa


Tài liệu tham khảo

Lee C-Y, Chen X, Romanelli RJ, Segal JB. Forces influencing generic drug development in the United States: a narrative review. J Pharmaceutical Policy and Practice. 2016;9(1):1–6.

Davit B, Braddy AC, Conner DP, Yu LX. International guidelines for bioequivalence of systemically available orally administered generic drug products: a survey of similarities and differences. AAPS J. 2013;15(4):974–90.

Huh KY, Kim E, Lee S, Yoo H, Yoon S, Yu K-S, et al. Current bioequivalence study designs in South Korea: a comprehensive analysis of bioequivalence study reports between 2013 and 2019. Front Pharmacol. 2021;12:651790.

Simoens S, De Coster S. Sustaining generic medicines markets in Europe. Journal of Generic Medicines. 2006;3(4):257–68.

Glerum PJ, Maliepaard M, de Valk V, Burger DM, Neef K. Drug switching in the Netherlands: a cohort study of 20 active substances. BMC Health Serv Res. 2020;20(1):650.

Colgan S, Faasse K, Martin LR, Stephens MH, Grey A, Petrie KJ. Perceptions of generic medication in the general population, doctors and pharmacists: a systematic review. BMJ Open. 2015;5(12):e008915.

Ryu M, Kim J. Perception and attitude of Korean physicians towards generic drugs. BMC Health Serv Res. 2017;17(1):1–9.

Leclerc J, Thibault M, Midiani Gonella J, Beaudoin C, Sampalis J. Are generic drugs used in cardiology as effective and safe as their brand-name counterparts? A systematic review and meta-analysis Drugs. 2020;80(7):697–710.

Gao J, Seki T, Kawakami K. Comparison of adherence, persistence, and clinical outcome of generic and brand-name statin users: A retrospective cohort study using the Japanese claims database. J Cardiol. 2021;77(5):545–51.

Gagne JJ, Choudhry NK, Kesselheim AS, Polinski JM, Hutchins D, Matlin OS, et al. Comparative effectiveness of generic and brand-name statins on patient outcomes: a cohort study. Ann Intern Med. 2014;161(6):400–7.

Kaló Z, Holtorf A-P, Alfonso-Cristancho R, Shen J, Ágh T, Inotai A, et al. Need for multicriteria evaluation of generic drug policies. Value in health. 2015;18(2):346–51.

Andersson K, Sonesson C, Petzold M, Carlsten A, Lönnroth K. What are the obstacles to generic substitution? An assessment of the behaviour of prescribers, patients and pharmacies during the first year of generic substitution in Sweden. Pharmacoepidemiol Drug Saf. 2005;14(5):341–8.

Kim YI, Kim Y-Y, Yoon JL, Won CW, Ha S, Cho K-D, et al. Cohort Profile: National health insurance service-senior (NHIS-senior) cohort in Korea. BMJ Open. 2019;9(7):e024344.

Lee J, Lee K-E, Park S, Jun KY. Validation of the Patient Health Questionnaire-9 for screening depressive disorders among Korean employees: a longitudinal study of the National Health Examination data. Int J Environ Res Public Health. 2022;19(7):3780.

Chong PH, Seeger JD, Franklin C. Clinically relevant differences between the statins: implications for therapeutic selection. Am J Med. 2001;111(5):390–400.

Lennernäs H, Fager G. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors: similarities and differences. Clin Pharmacokinet. 1997;32:403–25.

Wong M, Jiang J, Griffiths S. Switching of antihypertensive drugs among 93 286 Chinese patients: a cohort study. J Hum Hypertens. 2010;24(10):669–77.

Wei MY, Ito MK, Cohen JD, Brinton EA, Jacobson TA. Predictors of statin adherence, switching, and discontinuation in the USAGE survey: Understanding the use of statins in America and gaps in patient education. J Clin Lipidol. 2013;7(5):472–83.

Kesselheim AS, Gagne JJ, Eddings W, Franklin JM, Ross KM, Fulchino LA, et al. Prevalence and predictors of generic drug skepticism among physicians: results of a national survey. JAMA Intern Med. 2016;176(6):845–7.

Gawron AJ, Feinglass J, Pandolfino JE, Tan BK, Bove MJ, Shintani-Smith S. Brand name and generic proton pump inhibitor prescriptions in the United States: insights from the national ambulatory medical care survey (2006–2010). Gastroenterol Res Pract. 2015;2015:689531.

Herink M, Ito MK. Medication induced changes in lipid and lipoproteins. 2015.

Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1082–143.

Dimick JB, Ryan AM. Methods for Evaluating Changes in Health Care Policy: The Difference-in-Differences Approach. JAMA. 2014;312(22):2401–2.

Dawson R. How significant is a boxplot outlier? J Stat Educ. 2011;19(2):1–13.

Desai RJ, Sarpatwari A, Dejene S, Khan NF, Lii J, Rogers JR, et al. Differences in rates of switchbacks after switching from branded to authorized generic and branded to generic drug products: cohort study. BMJ. 2018;361:k1180.

Brito JP, Ross JS, Sangaralingham L, Dutcher SK, Graham DJ, Wang Z, et al. Comparative effectiveness of generic vs brand-name levothyroxine in achieving normal thyrotropin levels. JAMA Netw Open. 2020;3(9):e2017645-e.

Desai RJ, Sarpatwari A, Dejene S, Khan NF, Lii J, Rogers JR, et al. Comparative effectiveness of generic and brand-name medication use: A database study of US health insurance claims. PLoS Med. 2019;16(3):e1002763.

Katcher HI, Hill AM, Lanford JL, Yoo JS, Kris-Etherton PM. Lifestyle approaches and dietary strategies to lower LDL-cholesterol and triglycerides and raise HDL-cholesterol. Endocrinol Metab Clin North Am. 2009;38(1):45–78.

Peters JR, Hixon DR, Conner DP, Davit BM, Catterson DM, Parise CM. Generic drugs–safe, effective, and affordable. Dermatol Ther. 2009;22(3):229–40.

Hamada Y, Uchida M, Arai S, Yamazaki K, Takeda M, Arai K, et al. Analysis of patients’ request to switch from a generic drug to the original drug in external prescriptions. Journal of Pharmaceutical Health Care and Sciences. 2020;6(1):27.

Lee J-H, Choi Y-J, Lee SH, Sung N-J, Kim S-Y, Hong JY. Association of the Length of Doctor-Patient Relationship with Primary Care Quality in Seven Family Practices in Korea. JKMS. 2013;28(4):508–15.

Howard JN, Harris I, Frank G, Kiptanui Z, Qian J, Hansen R. Influencers of generic drug utilization: a systematic review. Res Social Adm Pharm. 2018;14(7):619–27.

Shrank WH, Liberman JN, Fischer MA, Girdish C, Brennan TA, Choudhry NK. Physician perceptions about generic drugs. Ann Pharmacother. 2011;45(1):31–8.

Thông tin
Thông tin xuất bản

Lipids in Health and Disease

Tập 22 Số 1

Thông tin tác giả